DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for disorder of appendix — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDisorder of appendix maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for disorder of appendix is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
guanosine monophosphate reductase (GMPR) — GMPR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5gpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2BLE · 1.9 Å · ligand GUANOSINE-5'-MONOPHOSPHATE (5GP). Experimental structure, not a prediction.
What the evidence adds up to
A 1919 review of appendix specimens found that many removed at surgery showed only lymphoid hyperplasia without any signs of inflammatory exudation, yet patients had been operated on for definite symptoms of subacute or chronic appendical disturbance. The authors credit Barss for first calling attention to this, noting that Barss removed seven such appendixes from children under 14. A 1935 paper acknowledges that surgeons continue to remove appendixes for so-called chronic appendicitis despite pathologists freely admitting that definite inflammation is often absent; the authors note that statistics on after-histories lead to various conclusions, though enough favourable reports encourage the practice.
A 2010 case report describes a young woman admitted with severe central abdominal pain radiating to the right iliac fossa, anorexia, rigors and vomiting, who had undergone open appendectomy four years earlier for a gangrenous appendix. She was found to have appendicitis in a remaining duplicate appendix, a rare phenomenon that can cause diagnostic dilemmas if not recognised. A 2016 review states that cancers of the appendix are rare, mostly found accidentally during appendectomies for appendicitis, with the majority being carcinoid, adenoma, or lymphoma. Adenocarcinomas constitute about 0.08% of all cancers, and treatment remains controversial; the authors report a 57-year-old man with mucinous adenocarcinoma treated with appendectomy.
The 2016 review notes that benign conditions are treated with surgery alone, lymphomas require chemotherapy, and carcinoid syndrome can be treated with somatostatin analogues. No controlled trials, survival data, or response rates are given for any of these treatments in the abstracts. The 1919 and 1935 papers highlight that many appendixes are removed without clear pathological inflammation, yet the clinical benefit of this practice remains debated based on the evidence presented.
What is still missing are prospective trials comparing surgery to observation for suspected chronic appendicitis, reliable biomarkers to distinguish true inflammation from lymphoid hyperplasia, and any randomised data on adjuvant therapy for appendix cancers. Patient stratification by tumour type and stage is absent from these reports, and no funding for such studies is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMJ Case Reports · 2010 · 6 citations
Appendicitis in a duplex appendix mimicking intussusception: Figure 1
AbstractAppendicitis in a remaining duplicate appendix is a rare phenomenon and we report such a case. The unusual presentation of this anomaly can cause diagnostic dilemmas. Awareness of this condition is important because failure to recognise the condition may lead to errors in diagnosis and subsequent management.
A young woman was admitted with a 3 day history of sudden onset, severe, central abdominal pain radiating towards the right iliac fossa, anorexia, rigors and vomiting. Her only significant past history was open appendectomy 4 years previously for a gangrenous appendix. The patient was pyrexial on admission but haemodynamically …
THE CLINICAL SIGNIFICANCE OF LYMPHOID HYPERPLASIA OF THE APPENDIX
AbstractIn the course of the past fifteen years, one of us, working in the pathologic laboratories at the New York and Bellevue Hospitals, has been almost daily impressed by the fact that, of all appendixes removed at operation, a very considerable number revealed no noteworthy microscopic alterations other than lymphoid hyperplasia, with or without the association of moderate sclerotic changes in the connective tissues. Signs of inflammatory exudation in the appendix were missing, and yet the patients had been subjected to operation because of definite symptoms of appendical disturbances of a subacute or chronic nature. With the exception of a paper by Barss,<sup>1</sup>to whom full credit should be given for first calling attention to the significance of these changes, the literature on the subject appears to be silent. Barss removed seven such appendixes at operation, all of them from children under the age of 14. In our records
AbstractThe question as to what appendicitis is and whether it ever exists has long since become trite. That there is a clinical entity consisting of a disorder of the appendix is believed by most surgeons. Many appendixes continue to be removed because of so-called chronic appendicitis. If there were no virtue in this practice one would expect it to present indications of ceasing to be the vogue. Statistics compiled from studies of the after-histories of patients whose appendixes have been removed because the organs seemed to be disturbers of the peace lead to various conclusions. Enough favorable reports1have been given and sufficient observations have been made in their own practices to encourage the majority of surgeons to continue to remove appendixes because of complaints. This is in spite of the fact that surgeons2as well as pathologists freely admit that definite inflammation
International Journal of Research in Medical Sciences · 2016 · 0 citations · open access
Cancers of the appendix: a case report and review of the literatures
AbstractCancers of the appendix are rare. Most of them are found accidentally on appendectomies performed for appendicitis. Majority of the tumors are carcinoid, adenoma, and lymphoma. Adenocarcinomas of appendix constitute about only 0.08% of all cancers and the treatment remains controversial. Here we are reporting a 57 year old man presented with symptoms of appendicitis, diagnosed with mucinious adenocarcinoma of the appendix. The patient was treated with appendectomy. We performed a review of literature on tumors of the appendix. Benign conditions are treated with surgery alone. For lymphomas chemotherapy are required and carcinoid syndrome can be treated with somatostatin analogues.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
